WO2005062810A3 - Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide - Google Patents

Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide Download PDF

Info

Publication number
WO2005062810A3
WO2005062810A3 PCT/US2004/042586 US2004042586W WO2005062810A3 WO 2005062810 A3 WO2005062810 A3 WO 2005062810A3 US 2004042586 W US2004042586 W US 2004042586W WO 2005062810 A3 WO2005062810 A3 WO 2005062810A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetraarsenic
decaoxide
primary
treatment
neoplastic diseases
Prior art date
Application number
PCT/US2004/042586
Other languages
French (fr)
Other versions
WO2005062810A2 (en
Inventor
Richard D Rotondo
Original Assignee
Mediscovery Llc
Richard D Rotondo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediscovery Llc, Richard D Rotondo filed Critical Mediscovery Llc
Publication of WO2005062810A2 publication Critical patent/WO2005062810A2/en
Publication of WO2005062810A3 publication Critical patent/WO2005062810A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention is directed to tetraarsenic decaoxide to treat cancer in mammals. The invention also relates to using tetraarsenic decaoxide as a means to treat cancer. The tetraarsenic decaoxide can be either encapsulated or unencapsulated.
PCT/US2004/042586 2003-12-18 2004-12-20 Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide WO2005062810A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53048703P 2003-12-18 2003-12-18
US60/530,487 2003-12-18
US1669704A 2004-12-17 2004-12-17
US11/016,697 2004-12-17

Publications (2)

Publication Number Publication Date
WO2005062810A2 WO2005062810A2 (en) 2005-07-14
WO2005062810A3 true WO2005062810A3 (en) 2006-01-05

Family

ID=34742373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/042586 WO2005062810A2 (en) 2003-12-18 2004-12-20 Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide

Country Status (1)

Country Link
WO (1) WO2005062810A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101536986B (en) * 2009-04-16 2011-05-04 北京圣医耀科技发展有限责任公司 Sodium alginate targeted sustained release microsphere vascular occlusive agent containing Sorafenib as well as preparation and application thereof
CN108066359A (en) * 2016-11-09 2018-05-25 凯马斯株式会社 The pharmaceutical composition for being used to inhibit metastasis of cancer comprising tetraarse-nic oxide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183385A1 (en) * 1997-10-15 2002-12-05 Ellison Ralph M. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183385A1 (en) * 1997-10-15 2002-12-05 Ellison Ralph M. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRISDON A.K. ET AL: "Matrix-isolation studies of the vaporisation of arsenic(v) oxide: the characterisation of molecular species As40n(n=7-10)by infrared spectroscopy.", JOURNAL OF THE CHEMICAL SOCIETY, DALTON TRANSACTIONS, INORGANIC CHEMISTRY., vol. 12, 1986, pages 2725 - 2730, XP008054830 *

Also Published As

Publication number Publication date
WO2005062810A2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
WO2006015263A3 (en) Lonidamine analogs
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
WO2005049000A3 (en) Treatment of phenylketonurias with bh4
PL364007A1 (en) Cosmetic treatment and mixture designed to improve appearance
HK1102544A1 (en) Use of herbal compositions in the manufacture of medicine for treating prostate cancer
WO2005046722A3 (en) Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
WO2006018632A3 (en) Cell therapy with exo 1
MXPA03008634A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases.
HRP20030874A2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2003212634A1 (en) Compounds useful in the treatment of cancer
PL375527A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
CA108023S (en) Lawn-mower
AU2003303374A8 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
HK1105288A1 (en) Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
WO2005062810A3 (en) Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2002005827A3 (en) Use of natural products in cancer treatment
CA99898S (en) Filter for aquariums
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2003231803A8 (en) Treatment of cancer with mefloquire
WO2005056054A3 (en) METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
AU2001230994A1 (en) Use of pentosan polysulfate to treat certain conditions of the prostate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase